HUE030811T2 - Netupitant és palonosetron terápiás kombinációi - Google Patents
Netupitant és palonosetron terápiás kombinációi Download PDFInfo
- Publication number
- HUE030811T2 HUE030811T2 HUE12784677A HUE12784677A HUE030811T2 HU E030811 T2 HUE030811 T2 HU E030811T2 HU E12784677 A HUE12784677 A HU E12784677A HU E12784677 A HUE12784677 A HU E12784677A HU E030811 T2 HUE030811 T2 HU E030811T2
- Authority
- HU
- Hungary
- Prior art keywords
- pain
- netupitant
- dose
- use according
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548514P | 2011-10-18 | 2011-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE030811T2 true HUE030811T2 (hu) | 2017-05-29 |
Family
ID=47178220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12784677A HUE030811T2 (hu) | 2011-10-18 | 2012-10-10 | Netupitant és palonosetron terápiás kombinációi |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9358228B2 (OSRAM) |
| EP (2) | EP2759298B1 (OSRAM) |
| JP (1) | JP2014530249A (OSRAM) |
| CN (3) | CN105412110B (OSRAM) |
| DK (1) | DK2744497T3 (OSRAM) |
| ES (1) | ES2579616T3 (OSRAM) |
| HK (1) | HK1198121A1 (OSRAM) |
| HU (1) | HUE030811T2 (OSRAM) |
| PL (1) | PL2744497T3 (OSRAM) |
| PT (1) | PT2744497T (OSRAM) |
| WO (1) | WO2013057554A2 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| TW202428273A (zh) | 2023-01-03 | 2024-07-16 | 瑞士商赫爾辛保健公司 | 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970007917B1 (ko) | 1989-11-28 | 1997-05-17 | 신텍스 인크. | 신규 삼환식 화합물 |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| WO2000048581A2 (en) * | 1999-02-18 | 2000-08-24 | Novartis Ag | Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| ES2226622T3 (es) | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1. |
| RS50932B (sr) | 2000-07-14 | 2010-08-31 | F. Hoffmann-La Roche Ag. | N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora |
| BRPI0116121B8 (pt) | 2000-12-14 | 2021-05-25 | F Hoffmannn La Roche Ag | composição de matriz de lipídeo auto-emulsificante para administração oral e seu processo de preparação |
| NZ541008A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating functional bowel disorders |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| JO2676B1 (en) * | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| EP2522664B1 (en) | 2004-07-01 | 2017-04-12 | OPKO Health, Inc. | Piperidine derivatives as NK1 antagonists |
| AU2007247851A1 (en) * | 2006-05-03 | 2007-11-15 | Relevare Aust. Pty Ltd | Methods and composition for treatment of inflammatory pain |
| NZ576237A (en) | 2006-10-24 | 2011-12-22 | Helsinn Healthcare Sa | Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
| US20100316678A1 (en) | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
| RS53491B1 (sr) * | 2009-11-18 | 2015-02-27 | Helsinn Healthcare Sa | Kompozicije za lečenje centralno posredovane mučnine i povraćanja |
-
2012
- 2012-10-10 PT PT127846772T patent/PT2744497T/pt unknown
- 2012-10-10 CN CN201510670710.XA patent/CN105412110B/zh active Active
- 2012-10-10 EP EP14165604.1A patent/EP2759298B1/en active Active
- 2012-10-10 CN CN201610834008.7A patent/CN106974912A/zh active Pending
- 2012-10-10 HU HUE12784677A patent/HUE030811T2/hu unknown
- 2012-10-10 PL PL12784677.2T patent/PL2744497T3/pl unknown
- 2012-10-10 JP JP2014536344A patent/JP2014530249A/ja active Pending
- 2012-10-10 CN CN201280051509.8A patent/CN103889423B/zh active Active
- 2012-10-10 US US14/351,113 patent/US9358228B2/en active Active
- 2012-10-10 EP EP12784677.2A patent/EP2744497B1/en active Active
- 2012-10-10 WO PCT/IB2012/002013 patent/WO2013057554A2/en not_active Ceased
- 2012-10-10 ES ES12784677.2T patent/ES2579616T3/es active Active
- 2012-10-10 DK DK12784677.2T patent/DK2744497T3/en active
-
2014
- 2014-08-14 HK HK14110976.1A patent/HK1198121A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103889423B (zh) | 2016-10-19 |
| JP2014530249A (ja) | 2014-11-17 |
| EP2744497B1 (en) | 2016-04-06 |
| CN105412110A (zh) | 2016-03-23 |
| US20140256737A1 (en) | 2014-09-11 |
| ES2579616T3 (es) | 2016-08-12 |
| CN106974912A (zh) | 2017-07-25 |
| PL2744497T3 (pl) | 2016-10-31 |
| CN103889423A (zh) | 2014-06-25 |
| EP2759298B1 (en) | 2018-01-17 |
| EP2759298A1 (en) | 2014-07-30 |
| WO2013057554A2 (en) | 2013-04-25 |
| PT2744497T (pt) | 2016-07-18 |
| US9358228B2 (en) | 2016-06-07 |
| HK1194977A1 (zh) | 2014-10-31 |
| WO2013057554A3 (en) | 2013-07-11 |
| EP2744497A2 (en) | 2014-06-25 |
| DK2744497T3 (en) | 2016-08-01 |
| CN105412110B (zh) | 2018-05-25 |
| HK1198121A1 (en) | 2015-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wong et al. | Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain | |
| ES2241651T3 (es) | Utilizacion de la nicotina o de sus derivados y de la l-dopa en un medicamento destinado al tratamiento de enfermedades neurologicas, especialmente la enfermedad de parkinson. | |
| US20100035978A1 (en) | Combination of cannabinoids for the treatment of peripheral neuropathic pain | |
| ES2709849T3 (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxia | |
| de la Tremblaye et al. | Chronic unpredictable stress during adolescence protects against adult traumatic brain injury-induced affective and cognitive deficits | |
| Auchter et al. | Therapeutic benefits of methylene blue on cognitive impairment during chronic cerebral hypoperfusion | |
| Gamez et al. | Lithium for treatment of amyotrophic lateral sclerosis: much ado about nothing | |
| Gowdey | A guide to the pharmacology of placebos | |
| WO1993013764A1 (fr) | Preparation pharmaceutique a action antistress, de prevention du stress et nootrope | |
| ES2538088T5 (es) | Extractos vegetales de Sideritis y su uso para el aumento de la capacidad cognitiva | |
| HUE030811T2 (hu) | Netupitant és palonosetron terápiás kombinációi | |
| ES2952610T3 (es) | Métodos para tratar o aliviar trastornos mentales y síntomas asociados | |
| ES2356371T3 (es) | Medicamentos terapéuticos para inducir tolerancia. | |
| Patel et al. | Emergency Critical Care of Accidental High Fall in a Wild Indian Palm Squirrel (Funambulus palmarum) | |
| TWI404542B (zh) | 用於治療抽動症及具有感覺運動門控不良之精神疾病的海州常山屬組合物 | |
| CN118593461B (zh) | 一种组合物、药物及其制备、检测、定位方法和用途 | |
| CN115770239B (zh) | 呋喃并色酮及药学上可接受的盐在制备治疗周围神经病变的药物中的应用 | |
| Mojarad et al. | Comparison of the antinociceptive effect of intrathecal versus intraperitoneal injection of paracetamol in neuropathic pain condition | |
| Allison | Total plasma ascorbic acid as index of stress in the rat | |
| Jayasri et al. | Research Article ISSN 2582-0109 | |
| Doongaji et al. | Clinical Experience with Prothipendyl Hydrochloride (Dominal)*—A New Tranquiliser | |
| Kokare et al. | A REVIEW ON THERAPEUTIC USES OF VANGA BHASMA | |
| Rebhun | Clinical observations on iproniazid in idiots with epilepsy | |
| Hou et al. | Features, Diagnosis, And | |
| Nurbek et al. | Features of the therapeutic scheme of ascaridosis treatment in Kazakhstan |